Placebo | ||||
Patient no. | Age yrs | Sex | FEV1 % pred | Daily dose μg |
Placebo | ||||
1 | 11 | M | 83 | SLB intermittent |
2 | 10 | M | 92 | SLB intermittent |
3 | 12 | F | 75 | FLT 100 × 2 |
4 | 12 | F | 91 | SLB intermittent |
5 | 8 | F | 95 | SLB intermittent |
6 | 10 | M | 93 | SLB intermittent |
7 | 11 | F | 88 | BDS 200 × 2 |
8 | 11 | M | 95 | SLB intermittent |
9 | 11 | M | 88 | SLB intermittent |
10 | 10 | M | 90 | SLB intermittent |
11 | 10 | F | 79 | SLB intermittent |
12 | 10 | M | 77 | SLB intermittent |
13 | 11 | M | 78 | SLB intermittent |
14 | 10 | F | 80 | FLT 100 × 2 |
15 | 9 | F | 89 | SLB intermittent |
Montelukast | ||||
1 | 9 | F | 77 | FLT 100 × 2 |
2 | 12 | F | 98 | SLB intermittent |
3 | 8 | M | 105 | BDS 200 × 2 |
4 | 10 | M | 76 | SLB intermittent |
5 | 11 | M | 92 | SLB intermittent |
6 | 9 | M | 77 | BDS 200 × 2 |
7 | 9 | M | 75 | SLB intermittent |
8 | 12 | M | 100 | SLB intermittent |
9 | 9 | M | 100 | SLB intermittent |
10 | 12 | F | 93 | SLB intermittent |
11 | 8 | M | 100 | SLB intermittent |
12 | 6 | F | 85 | SLB intermittent |
13 | 8 | F | 95 | SLB intermittent |
14 | 9 | M | 87 | SLB intermittent |
15 | 9 | M | 91 | BDS 200 × 2 |
FEV1: forced expiratory volume in one second; M: male; F: female; SLB: salbutamol; FLT: fluticasone; BDS: budesonide.